Fate Therapeutics (FATE), a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.
FATE’s immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors.
FATE's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders.
Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; a research collaboration partnership with the University of California San Diego to develop off-the-shelf chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. It also has a strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells.
Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
March 30, 2020
RegMed Investors’ (RMi) closing bell: the cell/gene therapy sector moves to the upside and stays there
March 27, 2020
RegMed Investors’ (RMi) closing bell: volatility strikes to the heart of cell/gene therapy sector and its sentiment indicator
March 27, 2020
RegMed Investors’ (RMi) pre-open: I’m worried about share pricing sustainability
March 25, 2020
RegMed Investors’ (RMi) closing bell: stimulus inspires markets another 5% gain after Tuesday’s 11% incline
March 24, 2020
RegMed Investors’ (RMi) closing bell: cell and gene therapy recover as volume moves the ladder of inclines
March 20, 2020
RegMed Investors’ (RMi) closing bell: whiplash, fear, panic and quadruple witching fuel volatility
March 20, 2020
RegMed Investors’ (RMi) pre-open: whipsaw, a big swing and a “limit up”
March 19, 2020
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector rises like the mythological phoenix
March 19, 2020
RegMed Investors’ (RMi) pre-open: bada bing bada boom and calling it as it should be the Wuhan virus from where it emanated
35 companies, 1 interpreter!
Insight, foresight and recommendation
Fate Therapeutics (FATE) – Two wordds - "on fire" having started 2018 at $6.30, saw a high of $9.39 and started February at $9.33 with a low of $7.85 jumping to $8.76 on 2/16 ... as investors kept the momentum going. It’s still in the earliest stages of development, but FATE has taken a shotgun approach to immunotherapy and cell therapy. It starts with induced pluripotent stem cells, which are then coaxed to transform into various immune cells, including natural killer cells (NKs), T-cells, and CD34+ cells. The idea is to create an off-the-shelf cellular immunotherapy production platform using stem cells. Despite the euphoria at the moment, the company's future will be determined in the clinic -- and there's a long way to go. One of MY favorites, it will twitch with dips ... near term - time will tell if it's a winner, I'd BET on this "horse" although many sessions will not stay in the gate.
buyMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.